SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as investors closely monitor a high-stakes legal dispute with Nippon Shinyaku regarding the distribution rights for its Duchenne muscular dystrophy therapy, Deramiocel. The community is actively discussing the impact of this litigation on the upcoming August PDUFA date, with many bullish investors framing the lawsuit as a strategic catalyst that could return full commercial rights to Capricor ahead of the drug's anticipated approval.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending as retail investors react to a combination of workforce restructuring, record-breaking trading volumes, and bullish anticipation for new revenue streams like AI-driven trading tools and prediction markets. Community members are actively debating the stock's potential for a breakout, with many focusing on the impact of increased platform engagement during major sporting and market events.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is attracting significant institutional interest as the community anticipates imminent Phase 3 52-week data, which is widely viewed as a major catalyst for potential M&A activity. Traders are actively discussing the stock's tight float and the strategic significance of recent supply agreements alongside upcoming conference presentations.

Fermi, Inc. engages in the development of energy infrastructure. It intends to develop an energy and data center development campus to support the needs of to-be-built AI infrastructure. The company was founded by Rick Perry, Toby Neugebauer and Griffin Perry on January 10, 2025 and is headquartered in Amrillo, TX.

Fermi Inc

Fermi LLC

Fermi LLC is experiencing heightened trading volume and volatility as investors speculate on potential data center tenant agreements amid ongoing boardroom leadership conflicts. Community sentiment remains polarized, with some traders optimistic about the company's energy infrastructure assets while others are wary of the persistent management drama and the lack of confirmed commercial contracts.

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SPCX is experiencing significant volatility as market participants debate the stock's massive valuation and its status as a high-profile IPO. The community is sharply divided, with many retail investors expressing concerns over a potential "rug pull" and long-term downside, while others view the pullback as a buying opportunity.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is facing intense community skepticism and frustration as the stock continues to trade near all-time lows despite sustained revenue generation. Investors are actively debating potential buyout scenarios and the impact of the company's siRNA pipeline while pointing to perceived management incompetence and heavy short interest as primary drivers of recent volatility.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure NV

uniQure is surging after the FDA reversed its previous stance and now allows the company to use three-year Phase I/II data for an accelerated approval BLA filing, effectively pulling forward the commercialization timeline for its Huntington's disease gene therapy. The community is actively discussing the significant regulatory win and the potential for a rapid re-rating, with traders highlighting the strategic importance of the ClearPoint navigation system to the procedural rollout.

SPDR Series Trust - State Street SPDR S&P Biotech ETF

SPDR S&P Biotech ETF

The SPDR S&P Biotech ETF is trending as investors rotate back into the sector, bolstered by a wave of M&A activity and positive data readouts for key oncology therapies. The community is actively discussing the potential for a sustained breakout, while closely monitoring clinical trial milestones and regulatory updates that act as primary catalysts for the ETF's performance.

Direxion Shares ETF Trust - Direxion Daily S&P Biotech Bear 3X ETF

Direxion Daily S&P Biotech Bear 3X Shares

LABD is experiencing heightened trading activity as the community remains divided over whether to capitalize on the biotech sector's volatility through short-term scalp trades or hold despite significant losses from the ETF's prolonged decline. Discussions are centered on the upcoming influence of key economic figures like Kevin Warsh, the impact of XBI's technical channel breakouts, and the recurring behavioral patterns traders are attempting to exploit during this period of market uncertainty.

Arqit Quantum, Inc. engages in the provision of cybersecurity services via satellite and terrestrial forms. Its product is QuantumCloud which secures devices with cloud-based quantum encryption. The company was founded by David John Williams and David James Bestwick on April 26, 2021 and is headquartered in London, the United Kingdom.

Arqit Quantum Inc

Arqit Quantum is experiencing significant momentum as investors pivot toward quantum-safe cybersecurity, with the stock drawing attention for its low float and heavy institutional ownership. The community is actively discussing its potential for a parabolic squeeze, citing recent partnerships and the critical industry demand for post-quantum cryptographic solutions.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$WRD  Mobileye moves from AV stack to operations when other AV tech providers have announced that they would move from operations(to AV stack only. 

Mobileye to establish vertically integrated robotaxi business
https://www.mobileye.com/news/mobileye-to-establish-vertically-integrated-robotaxi-business/

New initiative extends Mobileye beyond self-driving-system supply and is additive to existing automaker and mobility-partner programs

Mobileye

Mobileye to establish vertically integrated robotaxi business | Mobileye Blog

StockTwits for iOS

WeRide Inc. - ADR

  Mobileye moves from AV stack to operations when other AV tech providers have announced that they would move from operations(to AV stack only. 

Mobileye to establish vertically integrated robotaxi business


Niels

@NLZ My take is that Mobileye can&#39;t win enough customers/is losing some of them, therefore they go into the capital heavy business in a try to keep them relevant

StockTwits Web

 My take is that Mobileye can't win enough customers/is losing some of them, therefore they go into the capital heavy business in a try to keep them relevant

@Luke113 
I think you’re right to say they are loosing market share and relevance, especially in China. A huge market, that is shifting to export oriented, while technology developments n Advanced Adas are moving fast.

Huawei, Momenta are dominant in software, while WeRide is emerging. They’ll likely loose Zeekr platform, as Geely pushes for their in-house programs (g-pilot). Zeekr 001 refresh in 2025 was the clearest evidence. 

On chip level, China is moving to domestic silicon (Horizon J6, AD1000, or in-house developed (like BYD, XPeng and NIO). I don’t think MobilEye ships their own silicon (apart from legacy programmes) in China (just their Supervision software).

I’m not sure what triggered this move. They do have emerging Robotaxi presence in Europe, especially Germany (With Moia and VW ID.Buzz). That’s as a technology provider. 

This shift is different. I think they’ll move towards an asset light model, where they’ll leverage their OEM relationships, is my guess.

Nachhaltige Mobilität trifft auf innovatives Design: Der ID. Buzz ist der Elektro-Van der Zukunft. Jetzt mehr erfahren!

Volkswagen-nutzfahrzeuge

Der ID. Buzz: Elektro-Van für die mobile Zukunft

 
I think you’re right to say they are loosing market share and relevance, especially in China. A huge market, that is shifting to export oriented, while technology developments n Advanced Adas are moving fast.

Huawei, Momenta are dominant in software, while WeRide is emerging. They’ll likely loose Zeekr platform, as Geely pushes for their in-house programs (g-pilot). Zeekr 001 refresh in 2025 was the clearest evidence. 

On chip level, China is moving to domestic silicon (Horizon J6, AD1000, or in-house developed (like BYD, XPeng and NIO). I don’t think MobilEye ships their own silicon (apart from legacy programmes) in China (just their Supervision software).

I’m not sure what triggered this move. They do have emerging Robotaxi presence in Europe, especially Germany (With Moia and VW 

). That’s as a technology provider. 

This shift is different. I think they’ll move towards an asset light model, where they’ll leverage their OEM relationships, is my guess.